Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Neuromed Deal With Alza Will Accelerate Commercialization Strategy

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.

You may also be interested in...



Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain

Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.

Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain

Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.

Merck Signs On For Neuromed’s Chronic Pain Agent

Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS065947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By